RNA — Atrium Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2093101 ·
Last close
$8.40
Market Cap
$143.69M
52W High
$16.77
52W Low
$7.63
ADV30
384,975
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,004,000 | — | -22,618,000 | -20,186,000 | 280,512,000 | 72,334,000 | 65,936,000 |
| Mar 2026 | 19,635,000 | — | -17,280,000 | -16,633,000 | 292,360,000 | 267,849,000 | 58,256,000 |
| Dec 2025 | 859,000 | — | -48,035,000 | -48,069,000 | 278,353,000 | 270,000,000 | 71,066,000 |
| Sep 2025 | — | — | — | — | 277,544,000 | 270,000,000 | 64,691,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,761,000
Investing CF
$-3,195,000
Financing CF
$341,220,000
CapEx
$-3,195,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.41
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$12,128,000
Inventory
—
Receivables
$15,000,000
ST Investments
—
EBIT TTM
$-117,016,000
Pretax Income TTM
$-116,362,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$35,837,000
EBITDA
$-68,528,000
Free Cash Flow
—
Enterprise Value
$-85,002,536
Total Cash
$263,900,000
Total Debt
$1,683,000
Shares Out
17,105,643
Trailing EPS
$-5.44
Book Value
$12.54
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 18,618,000 | -76,814,000 | -76,684,000 | 278,353,000 | 71,066,000 | 207,287,000 | -41,129,000 |
| Dec 2024 | 10,897,000 | -13,218,000 | -25,122,000 | 7,186,000 | 68,294,000 | -61,108,000 | -22,553,000 |
| Dec 2023 | 9,764,000 | -6,386,000 | -6,385,000 | 10,293,000 | 80,912,000 | -70,619,000 | 56,390,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$292,360,000
Forward EPS
$-8.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DERM | Journey Medical Corp | $140.24M | $6.31 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $138.29M | $0.96 | — |
| KRRO | Korro Bio, Inc. | $149.61M | $10.16 | — |
| TLSA | Tiziana Life Sciences Ltd | $151.44M | $1.19 | — |
| NERV | Minerva Neurosciences, Inc. | $151.84M | $3.18 | — |
News headlines (Yahoo Finance, 1h cache)
Atrium Therapeutics Announces $50 Million Private Placement
2026-10-08 10:30 · Yahoo
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-21 20:30 · Yahoo
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
2026-09-06 10:44 · Yahoo
Atrium Therapeutics to Participate in Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
2026-08-13 20:44 · Yahoo
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation
2026-05-28 10:24 · Yahoo
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-21 02:46 · Yahoo
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
2026-08-28 19:42 · Yahoo
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
2026-08-13 12:00 · Yahoo
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
2026-08-06 13:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.